Pivotal, randomized, open-label study of Tumor Treating Fields (TTFields) in combination with PD-1 inhibitors or docetaxel, for second line treatment of non-small cell lung cancer (NSCLC).
A Phase 1 Dose Escalation and Phase 2 Randomized Double-Blind Study of Veliparib in Combination with Carboplatin and Etoposide as a Therapy of Treatment-Naïve Extensive Stage Disease Small Cell Lung Cancer.
A randomised Phase II open-label study with a Phase Ib safety lead-in cohort of ONCOS-102, an immune-priming GM-CSF coding oncolytic adenovirus, and pemetrexed/cisplatin in patients with unresectable malignant pleural mesothelioma.
Neo-adjuvant chemo/immunotherapy for the treatment of resectable stage IIIA non
small cell lung cancer (NSCLC): a phase II multicenter exploratory study
A retrospective, multicenter and observational study of Nivolumab monotherapytreatment in Subjects With Advanced or Metastatic Squamous (Sq) or Non-Squamous (Non-Sq) Non-Small Cell Lung Cancer (NSCLC) Who Have Received atLeast One Prior Systemic Regimens for the Treatment of Stage IIIb/IV NSCLC withinthe Expanded Access Program (EAP) in Spain. Protocol: GECP 16/05
Phase II study with BIBF1120, an oral inhibitor of fibroblast growth factor 1 as second-line treatment in patients with small cell lung cancer and amplification of the fibroblast growth factor receptor 1 gene.
A randomised, double-blind, parallel group, placebo-controlled multicentre Phase III study to assess the efficacy and safety of olaparib versus placebo as adjuvant treatment in patients with germline BRCA1/2 mutations and high risk HER2 negative primary breast cancer who have completed definitive local treatment and neoadjuvant or adjuvant chemotherapy.
Phase III randomized study of palbociclib with standard adjuvant endocrine treatment versus standard adjuvant endocrine monotherapy for primary breast cancer positive for hormone receptor (HR +) and HER2-negative. Protocol: AFT–05 ABCSG 42 BIG 14‐03
A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of PAlbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 therapy + Endocrine therapy after Induction treatment for Hormone Receptor Positive (HR+) / HER2-Positive Metastatic BreAst Cancer. Protocol: AFT –38
A Randomized double-bind phase II trial evaluating maintenance olaparib versus placebo in patients with platinum-sensitive advanced non-small cell lung cancer.
